Early Baldness in Males and Hormonal Changes

Sura A. Abdul Sattar  Fatin F. Al-Kazazz  Othman Saleh Al-Ogaidi

Department of Chemistry, College of Science, AL-Mustansiriy University, Iraq

E-mail: sura742003@yahoo.com.

Received 28/12/ 2015
Accepted 27/1/ 2016

Abstract:
Androgenetic alopecia (AGA) or baldness is a common form of hair loss, affecting men more than women. The exact causes and pathogenesis of baldness are not well understood. A search for new drug is still needed. This study aims to evaluate the role of gonadotropins hormones in hair loss in males and its possibility to be used as treatment target.

A total of 78 volunteers 43 with baldness and 35 healthy men were participated in this study. Their age ranged between (20-49) years, the studied groups were divided into two categories: firstly according to age (group1: 20-29 year), (group2: 30-39 year), and (group3: 40-49 year). Secondly according to baldness degree. LH and FSH were measured by using Enzyme Linked Immunosorbent Assay (ELISA) kits.

The results showed a significant decrease (p<0.05) in LH levels for baldness group with age (20-29) years in comparison to healthy group, while a non-significant difference was found in FSH or LH levels in other age groups. Furthermore, no correlation was found between the two hormones with baldness degree or with the age.

In conclusion, the lowering in LH levels for twentieth baldness men may be due to the increase in their dihydrotestosterone level as a result to getting sexual activation drugs or they had a hypopituitarism or indirectly disorder in their hypothalamus gland.

Key words: Androgenetic, baldness, gonadotropins, LH, FSH.

Introduction:
Male pattern baldness, known as androgenetic alopecia (AGA)[1], is a public condition, widely prevalence, which progresses with aging, affecting up to 80% of men and 50% of women in the course of their life[2][3]. AGA is caused by a gradual shorthand in the, length, diameter and dye of the hair [3]. There are three stages of hair cycle, anagen (active growth), catagen (inhibition of growth and atrophy of the hair follicle) and telogen (rest)[4]. Each strand of hair on the human body is at its own phase of development. The development gait of hair is nearly 0.5 inches /month, or 6 inches / year [5].
Two clinical features of male baldness have been known: a ready of scalp hair loss inherited from the father or grandfather(s) and a negative relation of scalp hair loss with the testes[6]. The pattern of male baldness was classified according to Hamilton-Norwood into 7 types. Type I scalp with no or lower recession of frontoparietal hair line, Type II and III scalps with moderate and deep recession, Types IV to VII scalps with severe recession and various degrees of absence of hair on the pate, Type VII being the most severe recession in which all that remains is a close band of hair beginning laterally frontal to the ears and extending posteriously low on the occiput[7]. The precise pathogenesis of androgenetic alopecia is not fully understood. Androgenetic alopecia is a phenotype which results from the interplay between genetic tendency and androgenic activity [8]. As the name reveal, the role of androgens and genetic tendency display to pattern hair loss due to gradual version of terminal hair into vellus hair [9].

The main male sex hormone is testosterone which is controlled by the release of luteinizing hormone (LH) from the anterior lobe of the pituitary gland. The production of male gametes depends on the collective action of the two gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) on the testis [10]. The action of LH is mediated through the production of testosterone by the Leydig cells. The synthesis and secretion of estrogens is stimulated by follicle-stimulating hormone (FSH). FSH is required for the determination of Sertoli cell number, and for induction and maintenance of normal sperm production. Both FSH and LH are controlled by the release of gonadotropin releasing hormone(GnRH) from the hypothalamus [10].

Finding of causes and medication hair loss is an important part of primary care. Jain R. reported that only two FDA-approved synthetic drugs, minoxidil and finasteride, are used to cure AGA with only 35 and 48% success, respectively; therefore, a search for new drug based on the mechanism of androgens action is still needed [11].

The aims of the present study are to evaluate the role of gonadotropins hormones in hair loss in males and the possibility to use as treatment target.

**Subjects and Methods**

A total of 78 volunteers 43 with baldness and 35 healthy men from AL-Mustansiriya University were participated in this study. The studied groups were divided into two categories: firstly according to age (group1: 20-29 year), (group 2: 30-39 year), and (group3: 40-40 year).Secondly according to baldness degree. Five milliliters of venous blood samples were collected from the baldness and the healthy controls groups then immediately transferred into plan tube and allowed to coagulate at room temperature then centrifuged at 3000 rpm for 5 min. The serum was separated and stored at (-20°C) until assay. LH and FSH were measured competitively by using Enzyme Linked Immunosorbent Assay (ELISA) kits (Human Company (Germany)) and performed according to the manufacturer's instructions. The statistical software SPSS program (v 15; Chicago, IL, USA) was used. The data were analyzed using unpaired t-test and person correlation coefficients. Differences were considered significant when \( P <0.05 \).

**Results and Discussion:**

Male baldness is a common form of hair loss, characterized by a gradual hair follicular miniaturization, caused by androgen hormones on a genetically susceptible hair follicle, in androgenic-dependent areas [12].
FSH secretion by the pituitary is under dual control by the hypothalamus and the gonads, where the hypothalamus produces GnRH, which maintains basal FSH secretion that in turn stimulates Sertoli cells in men, to undergo spermatogenesis [13].

The results presented in Table1 indicate the presence of a non significant decrease in FSH level in baldness groups compared with control group in three age groups (p˃0.05). It was reported that the FSH levels decreased in men due to hypopituitarism, hypophysectomy, adrenal tumors, and testosterone medications [14].

A significant decrease in LH level was observed in baldness group 1 (20-29 year) in comparison with their level of control group (p<0.05). While a non significant decrease in LH level was observed in baldness of both groups 2 (30-39year) and 3(40-49 year) in comparison with their control group (p˃0.05), as shown in Table 2.

Table 1: Mean values of FSH level in baldness and control groups

| Group(age(year)) | No | Mean (pg/ml) | ±SD | SE | P value |
|------------------|----|--------------|-----|----|---------|
| Group1 (20-29)   |    |              |     |    |         |
| Baldness         | 16 | 36.25        | 28.88 | 7.22 | 0.581   |
| Control          | 14 | 41.714       | 24.11 | 6.44 |         |
| Group2 (30-39)   |    |              |     |    |         |
| Baldness         | 15 | 37.133       | 34.28 | 8.851 | 0.179  |
| Control          | 10 | 21.200       | 14.17 | 4.481 |         |
| Group3 (40-49)   |    |              |     |    |         |
| Baldness         | 12 | 46.5         | 39.30 | 11.34 | 0.854  |
| Control          | 11 | 43.27        | 43.61 | 13.14 |         |

These results disagree with the result of Narad, S. et al who reported a non statistically significant difference found in serum hormonal profile (total testosterone, DHEA-S, FSH, LH and Insulin levels) of 50 men with severe premature balding before 30 years of age when compared with the same numbers of age matched[15]. Czubatka, I. et al reported that dihydrotestosterone is the most influential androgen and seems to play a very important role in the pathogenesis of androgenetic alopecia [16].

The mean values of LH/FSH ratio showed the presence of a significant decrease in baldness group in comparison to control in two age groups 1&2 while a non significant difference was observed in group 3 as shown in Table 3.

Table 3: Mean values of LH /FSH ratio in baldness and control groups

| Group (age(year)) | No | Mean | ±SD | SE | P value |
|------------------|----|------|-----|----|---------|
| Group1 (20-29)   |    |      |     |    |         |
| Baldness         | 16 | 1.766 | 0.68 | 0.12 | 0.002  |
| Control          | 14 | 3.595 | 2.25 | 0.60 |         |
| Group2 (30-39)   |    |      |     |    |         |
| Baldness         | 15 | 2.003 | 1.25 | 0.32 | 0.008  |
| Control          | 10 | 4.045 | 2.28 | 0.72 |         |
| Group3 (40-49)   |    |      |     |    |         |
| Baldness         | 12 | 6.51  | 3.19 | 2.8  | 0.29   |
| Control          | 11 | 8.2   | 1.44 | 0.43 |         |

Male androgenetic alopecia can begin at different stages of life, but its incidence increases with the patient's age. It usually applies to 25% of men aged 25 years, 40% of those in their 40 and over 50% of men at age 50 [17].

Table (4) shows the correlations between the hormones FSH, LH, and LH/FSH ratio with age (depending on Pearson's correlations) in sera of baldness group. The current study found a non significant correlation (p˃0.05) between hormones and age.

Table 4: Correlations between age and hormonal parameters.

| Hormone     | R value | P value |
|-------------|---------|---------|
| FSH         | 0.118   | 0.304   |
| LH          | -0.47   | 0.685   |
| LH/FSH      | 0.147   | 0.2     |

All patients were classified to 7 degrees of hair loss by the Hamilton-Norwood scale. The percentage ratio was presented in Figure 1. Baldness
degrees among studied male presented that the degree 3 represents the larger one while the 5& 6 degrees represent the smaller.

![Fig.1: Percentage values of male baldness degrees](image)

The hormones levels in sera of baldness groups were studied and evaluated according to baldness degree as shown in Figure 2 for FSH and Figure 3 for LH. The results indicted disorder increase of both FSH and LH with increase baldness degree.

![Fig.2: Mean values of FSH level according to baldness degree](image)

![Fig.3: Mean values of LH level according to baldness degree](image)

The baldness in men is a one of sexual male characterizers that this disorder due to LH alteration and this agree with our studied results. The explanation for the reasons in decreasing LH levels is an increasing in testosterone levels which are synthesized in Leydig cells present in interstitial testes tissues through feedback control [18].

**Conclusion:**

The lowering of LH levels in twentieth baldness men may be due to increase in their testosterone levels as a result to getting sexual activation drugs or they had a hypopituitarism or indirectly disorder in their hypothalamus gland.

**Recommendation**

We recommend the adoption of LH measurement in the diagnosis of baldness and use as a treatment according to their level.

**References:**

[1] Drake LA; Dinehart SM; Farmer ER; Goltz RW; Graham GF; Hordinsky MK; Lewis CW; Pariser DM; Webster SB; Whitaker, DC; Butler B; Lowery BJ; Price VH; Baden H; DeVillez RL; Olsen E;
and Shupack JL. 1996. Guidelines of care for androgenetic alopecia. J Am Acad Dermatol:35(3 pt 1):465–9.
[2] Batrinos ML. 2014. The endocrinology of baldness. Hormones. 13(2):197-212.
[3] Piraccini BM; and Alessandrin A. 2014. Androgenetic alopecia. G Ital Dermatol Venereol.149(1):15-24.
[4] Springer k; Brown M; and Stulberg DL. 2003. Common Hair Loss Disorders. Am Fam Physician. 68(1):93-102.
[5] Braun-Falco Otto.2000. Dermatology. Berlin: Springer. p. 1101
[6] Hamilton JB. 1960. Effect of castration in adolescent and young adult males upon further changes in the proportions of bare and hairy scalp. J Clin Endocrinol Metab . 20: 1309-1318.
[7] Norwood OT. 1975. Male pattern baldness: Classification and incidence. South Med J. 68: 1359-1365.
[8] Alfred Thomas J; Antonelli JA; Banez LL; Hoyo C; Grant D; Demark-Wahnefried W; Platz EA; Gerber L; Shuler K; Eyoh E; Calloway E; and Freed land SJ. 2013. Androgenetic Alopecia at Various Ages and Prostate Cancer Risk in an Equal Access Multiethnic Case Control Series of Veterans. Cancer Causes Control. 24(5): 1045–1052.
[9] Banka N; Bunagan MJ; and Shapiro J. 2013. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin. 31(1):129-40.
[10] Simoni M; Weinbauer GF; Gromoll J; and Nieschlag E. 1999. Role of FSH in male gonadal function. Ann Endocrinol (Paris). 60(2):102-6.
[11] Jain R; and De-Eknamkul W. 2014. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets. 18(7):787-806.
[12] Rossi A; Lorio A; Di Nunno D; Priolo L; Fortuna MC; Garelli V; Carlesimo M; Calvieri S; and Mari E. 2015. Conditions simulating androgenetic alopecia. J Eur Acad Dermatol Venereol. 29(7):1258-64.
[13] Newsholme E; &Leech T.2010. “Functional Biochemistry in Health and Disease”. Wiley-Blackwell Publishing. p.398.
[14] http://www.britannica.com/EBchecked/topic/212333/follicle-stimulating-hormone-FSH.
[15] Narad S; Pande S; Gupta M; and Chari S. 2013. Hormonal Profile in Indian Men with Premature Androgenetic Alopecia. Int J Trichology. 5(2): 69–72.
[16] Czubatka IU; Kmieć ML; and Dyła GB.2014. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Postepy Dermatol Alergol. 31(4): 207–215.
[17] Tosti A; Camacho-Martinez F; and Dawber R. 1999. Management of androgenetic alopecia. JEADV. 12:205–14.
الصلع المبكر عند الرجال والتغيرات الهرمونية

سرى أحمد عبدالله
فائز فاضل القزاز
عثمان صالح العكيدي

قسم الكيمياء، كلية العلوم، الجامعة المستنصرية.

الخلاصة:

داء الصلع هو شكل شائع من تساوق الشعر، يؤثر على الرجال أكثر من النساء. والسبب الحقيقي لحدوث الصلع ليست مفهومة جيدا ولا تزال هناك حاجة إلى البحث عن عقار جديد. تهدف هذه الدراسة إلى تقييم دور الهرمونات المنخفضة للمرضي في تساوق الشعر عند الذكور وإمكانية استخدامها كعلاج.

شارك في هذه الدراسة 78 متطوعا: 43 من الرجال المصابين بالصلع و35 رجلا من الاصحاب. تراحت أعمارهم بين (20-49) سنة. تم تقسيم المجموعات المدروسة إلى فئتين: الأولى وفقا لسن المجموعة الأولى (29-39 سنة)، المجموعة الثانية (30-39 سنة) والمجموعة الثالثة (40-49 سنة). وفقا لدرجة الصلع. تم قياس الهرمونات اللوتيتي والهرمون المحت للجرب باستخدام طريقة الأليزا.

أظهرت النتائج انخفاض معنوي في مستويات الهرمون اللوتيتي لمرضي الصلع البعض (20-29) سنة مقارنة مع مجموعة الاصحاب (p<0.05)، في حين تبين وجود اختلاف غير معنوي لهرمون الهرموني أوالهرمون المحت للجرب للجميع المجموعة الأخرى. علاوة على ذلك تبين عدم وجود علاقة بين الهرمونيين مع درجة الصلع أو مع التقدم في السن.

نستنتج أن خفض في مستويات LH للرجال المصابون بالصلع بعض العشرين قد يكون نتيجة الزيادة في مستوى DHEA-T أو بسبب تناول الأدوية المنخفضة جنسيا أو لديهم قصور تخامى أو بسبب غير مباشر كاضطراب في العقد تحت المهادي.

الكلمات المفتاحية: ذكرى، الصلع، كوناديوتروبين، هرمون المحت للجرب، والهرمون اللوتيتي.